Crossmark

Microbiota and short chain fatty acid relationships underlie clinical heterogeneity and identify key microbial targets in irritable bowel syndrome (IBS)

Crossref DOI link: https://doi.org/10.1038/s41598-025-19363-2

Published Online: 2025-10-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shin, Andrea S.

Xing, Yue

Waseem, Mohammed Rayyan

Siwiec, Robert

James-Stevenson, Toyia

Rogers, Nicholas

Bohm, Matthew

Wo, John

Lockett, Carolyn

Gupta, Anita

Kadariya, Jhalka

Toh, Evelyn

Anderson, Rachel

Dong, Amy

Xu, Huiping

Gao, Xiang
Funding

Funding for this research was provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (K23DK122015)

NIDDK (R03DK132446)
License Information

Text and Data Mining valid from 2025-10-09

Version of Record valid from 2025-10-09
More Information

Article History

Received: 18 September 2024

Accepted: 8 September 2025

First Online: 9 October 2025

Declarations

:

: AS serves as a consultant for Ardelyx, has served on an Advisory Board for Gemelli Biotech, and is an Advisor for Medis Labs, Inc.

: The study was approved by the Indiana University Institutional Review Board.

: Not applicable.

Document is current

Any future updates will be listed below